Immunitybio, Inc. · NASDAQ:IBRX
Cambridge Equities, LP reported a 24.70% stake in Immunitybio, Inc. (Schedule 13D/A)
Event Jul 31, 2026 · Filed Aug 6, 2026
Cambridge Equities, LP reported a 24.70% stake in Immunitybio, Inc., 261,705,814 shares, with active intent on Jul 31, 2026. Filed Aug 6, 2026 (Schedule 13D/A).
- Stake
- 24.70%
- Shares
- 261,705,814
- Intent
- Active
- What changed
- Stake changed
- Filed together
- 6 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Cambridge Equities, LP | 24.70% | 261,705,814 |
| MP 13 Ventures, LLC | 24.70% | 261,705,814 |
| NantWorks, LLC | 9.30% | 98,535,253 |
| Nant Capital, LLC | 29.60% | 339,465,528 |
| California Capital Equity, LLC | 10.00% | 106,511,412 |
| Patrick Soon-Shiong | 64.80% | 745,518,285 |